Botensilimab + Balstilimab in Platinum-Resistant Ovarian Cancer - OncoDaily Botensilimab plus balstilimab demonstrates durable responses in platinum-resistant ovarian cancer, overcoming immune resistance via Fc-enhanced CTLA-4 blockade.

Botensilimab + Balstilimab in Platinum-Resistant Ovarian Cancer

oncodaily.com/opinion/ovar...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #Botensilimab #Balstilimab #OvarianCancer

Agenus' Investigator's Forum 2025: BOT/BAL Advancing Immunotherapy in Solid Tumors - OncoDaily Agenus' Investigator's Forum 2025: BOT/BAL Advancing Immunotherapy in Solid Tumors / Agenus, Agenus' Investigator's Forum, Balstilimab, BATTMAN trial,

Agenus’ Investigator’s Forum 2025: BOT/BAL Advancing Immunotherapy in Solid Tumors

oncodaily.com/drugs/agenus...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #Agenus #Investigator’sForum #BOT/BAL #Balstilimab #Botensilimab #ColorectalCancer #IO #Immunotherapy #SolidTumors

Botensilimab and Balstilimab Achieves 21-Month Survival in mCRC and FDA Endorsement for Global Phase 3 Trial - OncoDaily Botensilimab and Balstilimab Achieves 21-Month Survival in mCRC and FDA Endorsement for Global Phase 3 Trial / Agenus, botensilimab, Cancer research,

Botensilimab and Balstilimab Achieves 21-Month Survival in mCRC and FDA Endorsement for Global Phase 3 Trial
@fda.gov

oncodaily.com/oncolibrary/...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #Botensilimab #Balstilimab #CRC #mCRC #CororectalCancer

Botensilimab and Balstilimab Show Durable Survival in MSS Colorectal Cancer: ESMO GI 2025 Update - OncoDaily Botensilimab plus balstilimab delivers 21-month overall survival in MSS colorectal cancer, per updated Phase 1b data at ESMO GI 2025.

Botensilimab and Balstilimab Show Durable Survival in MSS Colorectal Cancer: ESMO GI 2025 Update
@myesmo.bsky.social

oncodaily.com/oncolibrary/...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #Botensilimab #Balstilimab #MSSColorectalCancer #CRC #GIOnc #ESMOGI25

ImmunoGenesis Begins Innovative Clinical Trial for Advanced Cancers Combining IMGS-101 with Balstilimab and Zalifrelimab ImmunoGenesis has initiated a clinical trial investigating IMGS-101 alongside Balstilimab and Zalifrelimab for challenging cancers, including advanced prostate and pancreatic tumors.

ImmunoGenesis Begins Innovative Clinical Trial for Advanced Cancers Combining IMGS-101 with Balstilimab and Zalifrelimab #USA #Houston #ImmunoGenesis #IMGS-101 #Balstilimab

Breaking Barriers in Advanced Sarcoma Treatment - OncoDaily Breaking Barriers in Advanced Sarcoma Treatment / Andrea Bullock, Anthony El-Khoueiry, Apostolia M Tsimberidou, Balstilimab, botensilimab, Breelyn A. Wilky,

Breaking Barriers in Advanced Sarcoma Treatment

@cucancercenter.bsky.social

oncodaily.com/science/sarc...

#Balstilimab #Botensilimab #Cancer #FightAgainstCancer #GlobalFightAgaintsCancer ##JournalofClinicalOncology #MiNKTherapeutics #OncoDaily #Oncology #Sarcoma #Medicine #Health

Agenus and Tanner Pharma Partner to Expand Global Access to BOT/BAL - OncoDaily Agenus and Tanner Pharma Partner to Expand Global Access to BOT/BAL / Agenus, Balstilimab, botensilimab, cancer, OncoDaily, Oncology, Tanner Pharma Group

Agenus and Tanner Pharma Partner to Expand Global Access to BOT/BAL

oncodaily.com/insight/203713

#Agenus #Balstilimab #Botensilimab #Cancer #OncoDaily #Oncology #TannerPharmaGroup #Medicine #Health